Have you or your loved ones been diagnosed with advanced solid tumors cancer?

You may be eligible to participate in a advanced solid tumors cancer clinical trial.

Have you or your loved ones been diagnosed with advanced solid tumors cancer? You may be eligible to participate in a advanced solid tumors cancer clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Advanced Solid Tumors Cancer Clinical Trial
NCT03234712 | Phase 1 | Interventional
AbbVie
Sponsored by
AbbVie

Have you or your loved ones been diagnosed with advanced solid tumors cancer?

You may be eligible to participate in a advanced solid tumors cancer clinical trial.

Have you or your loved ones been diagnosed with advanced solid tumors cancer? You may be eligible to participate in a advanced solid tumors cancer clinical trial.

Active not recruiting

Male & Female

18 Years +

This study has recruited 62 Participants

This is an open-label, Phase 1, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-321 for participants with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). The study will consist of 2 phases: Dose Escalation Phase and Expansion Phase.